NCT02283905View on ClinicalTrials.gov

Amphotericin-B and Voriconazole for Pulmonary Blastomycosis

PHASE4TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions

Blastomycosis

Interventions

DRUG

amphotericin-B

continuously infused

DRUG

voriconazole

intravenously or orally administered

Trial Locations (1)

R2H 2A6

St. Boniface General Hospital, Winnipeg

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

University of Manitoba

OTHER

NCT02283905 - Amphotericin-B and Voriconazole for Pulmonary Blastomycosis | Biotech Hunter | Biotech Hunter